TrialLancet (London, England)2021

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Bijal D Shah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.